PROCEPT BioRobotics News

Analysts Are Bullish on These Healthcare Stocks: Accolade (ACCD), PROCEPT BioRobotics (PRCT)

TipRanksApr 26 20:05

PROCEPT BioRobotics Announces 12 Scientific Research Presentations On Aquablation Therapy For Treatment Of Benign Prostatic Hyperplasia At 2024 AUA Annual Meeting

PROCEPT BioRobotics Announces 12 Scientific Research Presentations On Aquablation Therapy For Treatment Of Benign Prostatic Hyperplasia At 2024 AUA Annual Meeting

BenzingaApr 23 20:03

PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting

Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trialsSAN JOSE, Cali

PROCEPT BioRobotics Apr 23 12:00

PROCEPT BioRobotics Announces Board Member Transition

TipRanksApr 20 05:42

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Price In Tune With Revenues

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) price-to-sales (or "P/S") ratio of 19x might make it look like a strong sell right now compared to the Medical Equipment industry in the United States,

Simply Wall StApr 15 22:00

PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas

SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative soluti

PROCEPT BioRobotics Apr 4 12:00

PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024

SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing trans

PROCEPT BioRobotics Apr 2 12:00

Procept Biorobotics Insider Sold Shares Worth $263,243, According to a Recent SEC Filing

Reza Zadno, Director, President, CEO, on March 18, 2024, sold 5,391 shares in Procept Biorobotics (PRCT) for $263,243. Following the Form 4 filing with the SEC, Zadno has control over a total of 241,3

MT NewswiresMar 21 22:48

PROCEPT BioRobotics Corp (PRCT) President and CEO Reza Zadno Sells Company Shares

Yahoo FinanceMar 21 07:01

Analysts Are Bullish on These Healthcare Stocks: Cormedix (CRMD), PROCEPT BioRobotics (PRCT)

TipRanksMar 13 00:20

This Insider Has Just Sold Shares In PROCEPT BioRobotics

We'd be surprised if PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shareholders haven't noticed that the President, Reza Zadno, recently sold US$428k worth of stock at US$46.67 per share. On the br

Simply Wall StMar 11 18:07

Procept Biorobotics Insider Sold Shares Worth $428,384, According to a Recent SEC Filing

Reza Zadno, Director, President, CEO, on March 06, 2024, sold 9,179 shares in Procept Biorobotics (PRCT) for $428,384. Following the Form 4 filing with the SEC, Zadno has control over a total of 246,7

MT NewswiresMar 8 23:10

EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics Corp (PRCT)

Yahoo FinanceMar 8 14:30

PROCEPT BioRobotics(PRCT.US) Director Sells US$970.64K in Common Stocks

$PROCEPT BioRobotics(PRCT.US)$ Director Krummel Thomas M sold 20,000 shares of Common Stocks on Mar 4, 2024 at an average price of $48.5321 for a total value of $970.64K.Source: Announcement What is s

Futu NewsMar 7 06:41

Procept Biorobotics Insider Sold Shares Worth $970,643, According to a Recent SEC Filing

Thomas M Krummel, Director, on March 04, 2024, sold 20,000 shares in Procept Biorobotics (PRCT) for $970,643. Following the Form 4 filing with the SEC, Krummel has control over a total of 65,631 share

MT NewswiresMar 7 05:57

Buy Rating Affirmed for PROCEPT BioRobotics Amid Strong Growth and Favorable Market Dynamics

TipRanksMar 1 13:59

Earnings Call: PROCEPT BioRobotics Sees 83% Revenue Surge in Q4

InvestingMar 1 03:44

Truist Securities Maintains Buy on PROCEPT BioRobotics, Raises Price Target to $58

Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and raises the price target from $55 to $58.

BenzingaFeb 28 23:18

PROCEPT BioRobotics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/28/2024 16% Truist Securities $55 → $58 Maintains Buy 01/09/2024 -6% Wells Fargo $44 → $47 Maintains Ov

BenzingaFeb 28 23:17

Analysts' Top Healthcare Picks: Alphatec Holdings (ATEC), PROCEPT BioRobotics (PRCT)

TipRanksFeb 28 20:40